Clinical trial information: NCT04492033 .doi:10.1200/JCO.2023.41.4_suppl.540Do-Youn OhJoon Oh ParkJin Won KimKyu-Pyo KimJeesun YoonTae-Yong KimSeung Tae KimYoung Suk ParkJeeyun LeeJi-Won KimAmerican Society of Clinical Oncology (ASCO)Journal of Clinical Oncology...
Moreover, 22 of the 24 patients enrolled to the trial achieved stable disease or better, which translated to a clinical benefit rate (CBR) of 92%. Notably, 7 patients continued to receive the regimen at the cutoff date; 5 of these patients had been on treatment for longe...
“The results from the phase 2 trial in biliary tract cancer continue to show the potential of CTX-009, which has demonstrated activity in a broad range of solid tumors. We are presently enrolling patients in two clinical studies of CTX-009 in the United States and expect to report initial ...
The study is currently activating sites with first patient in expected in 2022. Clinical trial information: NCT05513742 .doi:10.1200/JCO.2023.41.4_suppl.TPS281Marilyn FontaineSarah PilgrimThomas SchuetzAmerican Society of Clinical Oncology (ASCO)Journal of Clinical Oncology...
Clinical trial information: 251040.Olivia AranhaWashington University School of Medicine in St. Louis, St. Louis, MOMilind M. JavleDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TXMinori Koshiji Rosales...